Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Advances in digital pathology and artificial intelligence have presented the potential to build assistive tools for objective diagnosis, prognosis and therapeutic-response and resistance prediction. In this talk we will discuss our work on: (1) Data-efficient methods for weakly-supervised whole slide classification with examples in cancer diagnosis and subtyping (Nature BME, 2021), identifying origins for cancers of unknown primary (Nature, 2021) and allograft rejection (Nature Medicine, 2022) (2) Discovering integrative histology-genomic prognostic markers via interpretable multimodal deep learning (Cancer Cell, 2022; IEEE TMI, 2020; ICCV, 2021; CVPR, 2024; ICML, 2024). (3) Building unimodal and multimodal foundation models for pathology, contrasting with language and genomics (Nature Medicine, 2024a, Nature Medicine 2024b, CVPR 2024). (4) Developing a universal multimodal generative co-pilot and chatbot for pathology (Nature, 2024). (5) 3D Computational Pathology (Cell, 2024) (6) Bias and fairness in computational pathology algorithms (Nature Medicine, 2024).

Dr. Mahmood is an Associate Professor at Harvard Medical School and the Division of Computational Pathology at the Brigham and Women’s Hospital. He received his Ph.D. in Biomedical Imaging from the Okinawa Institute of Science and Technology, Japan and was a postdoctoral fellow at the department of biomedical engineering at Johns Hopkins University. His research interests include pathology image analysis, morphological feature, and biomarker discovery using data fusion and multimodal analysis. Dr. Mahmood is a full member of the Dana-Farber Cancer Institute / Harvard Cancer Center, an Associate Member of the Broad Institute of Harvard and MIT, and a member of the Harvard Bioinformatics and Integrative Genomics faculty.